Concepedia

Luke Ashcraft

LA

4

Publications

253

Citations

4

H-Index

2010

Active since

Affiliations

Cytokinetics (United States)(Current)

Luke Ashcraft is an author at Cytokinetics (United States) specializing in drug discovery, medicinal chemistry, and chromatin.

Top concepts

Publications per year

2010–2024

4

Publications

4

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Chih-Yuan Chuang, Scott E. Collibee, Luke Ashcraft et al. · Journal of Medicinal Chemistry · 2021 · 154 citations · Full text

Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295

Xiangping Qian, Andrew McDonald, Han-Jie Zhou et al. · ACS Medicinal Chemistry Letters · 2010 · 64 citations · Full text

, , +19

Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function

Scott E. Collibee, Gustave Bergnes, Chih-Yuan Chuang et al. · Journal of Medicinal Chemistry · 2021 · 25 citations · Full text

Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility

Antonio Romero, Luke Ashcraft, Aroop Chandra et al. · Journal of Medicinal Chemistry · 2024 · 10 citations · Full text

Rows per page

1–4 of 4